by Carregal-Romero, Susana, Fadón, Lucía, Berra, Edurne and Ruiz-Cabello, Jesus
Abstract:
In this review, the potential future role of microRNA-based therapies and their specific application in lung diseases is reported with special attention to pulmonary hypertension. Current limitations of these therapies will be pointed out in order to address the challenges that they need to face to reach clinical applications. In this context, the encapsulation of microRNA-based therapies in nanovectors has shown improvements as compared to chemically modified microRNAs toward enhanced stability, efficacy, reduced side effects, and local administration. All these concepts will contextualize in this review the recent achievements and expectations reported for the treatment of pulmonary hypertension.
Reference:
MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension. (Carregal-Romero, Susana, Fadón, Lucía, Berra, Edurne and Ruiz-Cabello, Jesus), In International Journal of Molecular Sciences, Multidisciplinary Digital Publishing Institute, volume 21, 2020.
Bibtex Entry:
@article{CarregalRomero:2020hka,
author = {Carregal-Romero, Susana and Fad{'o}n, Luc{'i}a and Berra, Edurne and Ruiz-Cabello, Jesus},
title = {{MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension.}},
journal = {International Journal of Molecular Sciences},
year = {2020},
volume = {21},
number = {9},
pages = {3253},
month = may,
publisher = {Multidisciplinary Digital Publishing Institute},
affiliation = {Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Paseo de Miram{'o}n 182, 20014 San Sebasti{'a}n, Spain.},
doi = {10.3390/ijms21093253},
pmid = {32375361},
pmcid = {PMC7246754},
language = {English},
rating = {0},
date-added = {2020-05-13T19:16:08GMT},
date-modified = {2020-10-07T09:51:48GMT},
abstract = {In this review, the potential future role of microRNA-based therapies and their specific application in lung diseases is reported with special attention to pulmonary hypertension. Current limitations of these therapies will be pointed out in order to address the challenges that they need to face to reach clinical applications. In this context, the encapsulation of microRNA-based therapies in nanovectors has shown improvements as compared to chemically modified microRNAs toward enhanced stability, efficacy, reduced side effects, and local administration. All these concepts will contextualize in this review the recent achievements and expectations reported for the treatment of pulmonary hypertension.},
url = {https://www.mdpi.com/1422-0067/21/9/3253},
local-url = {file://localhost/Users/jruizcabello/Documents/JRC/biblio/Papers-folder/Library.papers3/Files/7E/7E6EEEDC-FE03-43D4-90F4-3E37FA60D23A.pdf},
file = {{7E6EEEDC-FE03-43D4-90F4-3E37FA60D23A.pdf:/Users/jruizcabello/Documents/JRC/biblio/Papers-folder/Library.papers3/Files/7E/7E6EEEDC-FE03-43D4-90F4-3E37FA60D23A.pdf:application/pdf}},
uri = {url{papers3://publication/doi/10.3390/ijms21093253}}
}